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0.672; 95% conﬁdence interval, 0.466 to 0.969; p ¼ 0.034).Conclusions Ascorbic acid provides effective nephroprotection against CI-AKI and may form a part of effective prophylactic
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FoundationContrast induced-acute kidney injury (CI-AKI) is one of the
most widely discussed and debated topics in cardiovascular
medicine. The incidence of CI-AKI is increasing. This is
due to an increasing number of contrast media–enhanced
radiological procedures being performed and an increase in
the octogenarian population with comorbidities such as
hypertension, diabetes mellitus, and renovascular disease, all
of which predispose to renal impairment. It is therefore
imperative that more attention be given to develop a better
understanding of the etiology of CI-AKI, to devise novel
methods of its diagnosis at an earlier stage before renalmbridge University Hospitals NHS Foundation
; yDepartment of Internal Medicine, Cardio-
ospital, Lahore, Pakistan; and the zUniversity
of Cambridge, Cambridge, United Kingdom.
ave no relationships relevant to the contents of
3; revised manuscript received July 16, 2013,failure has occurred, and to formulate effective prophylactic
and therapeutic regimens to reduce its incidence.
Traditionally, ascorbic acid has been used as a dietary
supplement. Today there is strong evidence that it acts as
a potent antioxidant by scavenging physiologically relevant
reactive oxygen species (ROS) (1,2). As oxidative stress has
been implicated as a contributing factor in the etiology of
CI-AKI (3), use of ascorbic acid as a nephroprotective agent
is therefore logical.
See page 2176
Our objective was to assess whether ascorbic acid reduces
the incidence of CI-AKI. We reviewed randomized,
controlled trials (RCTs) that assessed its nephroprotective
role in reducing CI-AKI compared with placebo or other
pharmacological agents in patients undergoing coronary
angiography.
Abbreviations
and Acronyms
CI = conﬁdence interval
CI-AKI = contrast-induced
acute kidney injury
RCT = randomized,
controlled trial
ROS = reactive oxygen
species
RR = risk ratio
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Protocol. The research question,
search strategy, inclusion criteria,
and statistical analyses were pre-
speciﬁed.
Eligibility criteria. TYPESOF STU-
DIES. RCTs assessing the use of
ascorbic acid in reducing CI-AKI
compared with placebo or other
pharmacological treatments, in
patients undergoing coronary an-giography were reviewed. No language, publication date, or
publication status restrictions were imposed.
TYPES OF PARTICIPANTS. Participants of any age with or
without documented pre-existing renal impairment under-
going coronary angiography were considered.
TYPES OF INTERVENTION. Ascorbic acid alone (or with saline
solution hydration) was used in 1 treatment arm. The route
of administration of ascorbic acid could be oral and/or
intravenous. Patients in the comparison group could either
receive saline solution hydration and/or placebo/other
nephroprotective agent.
TYPES OF OUTCOME MEASURES. For a RCT to be included,
it had to report incidence of CI-AKI as an outcome
measure. CI-AKI was deﬁned as an absolute increase in
serum creatinine of 0.5 mg/dl (44 mmol/l) or a relative
increase of 25% from the baseline value after administra-
tion of contrast media during angiography.
Information sources. Electronic databases used were
MEDLINE, Embase, and Cochrane Central databases from
the date of inception until May 15, 2013, were systematically
searched. No limits were used for an electronic literature
search. Tangential electronic exploration of related articles
(i.e., using links to related references to search for additional
articles) was also performed. The last search was run on
May 20, 2013. Extensive hand searches of bibliographies of
relevant reviews and related journals were also done.
Search. Search terms included variants of vitamin C,
ascorbic acid, nephropathy, contrast nephropathy, contrast-
induced nephropathy, contrast media, contrast agent, kid-
ney, renal, angiography, and arteriography using text words
and MeSH terms. Search strategy using the MEDLINE
database was as follows.
SEARCH HISTORY.
1. MEDLINE; “vitamin C”.ti,ab; 14,581 results
2. MEDLINE; “ascorbic acid”.ti,ab; 22,487 results
3. MEDLINE; expASCORBICACID/; 34,524 results
4. MEDLINE; 1 OR 2 OR 3; 48,039 results
5. MEDLINE; kidney*.ti,ab; 311,331 results
6. MEDLINE; renal.ti,ab; 427,591 results
7. MEDLINE; exp KIDNEY/; 289,995 results
8. MEDLINE; “contrast induced nephropath*”.ti,ab;
868 results9. MEDLINE; “contrast nephropath*”.ti,ab; 239 results
10. MEDLINE; nephropathy.ti,ab; 36,572 results
11. MEDLINE; “contrast media”.ti,ab; 9,299 results
12. MEDLINE; “contrast agent*”.ti,ab; 17,645 results
13. MEDLINE; exp CONTRASTMEDIA/; 88,039 results
14. MEDLINE; 11 OR 12 OR 13; 95,541 results
15. MEDLINE; 5 OR 6 OR 7 OR 10; 722,617 results
16. MEDLINE; 8 OR 9; 1,064 results
17. MEDLINE; 14 AND 15; 10,603 results
18. MEDLINE; 16 OR 17; 10,786 results
19. MEDLINE; “angiograph*”.ti,ab; 130,279 results
20. MEDLINE; exp ANGIOGRAPHY/; 189,985 results
21. MEDLINE; “arteriograph*”.ti,ab; 17,695 results
22. MEDLINE; 19 OR 20 OR 21; 253,190 results
23. MEDLINE; 4 AND 18 AND 22; 10 results
Study selection. Eligibility assessment was performed by
1 author (U.S.) in an unblinded standardized manner using
a study eligibility form based on the Cochrane consumers
and communication review group’s data extraction template.
Random checks were made by another author (A.U.). The
title and abstract of the retrieved records were screened.
Conference abstracts and letters retrieved from electronic
databases were also included in screening process.
Data collection process. Data extraction was performed
using Cochrane consumers and communication review
group’s data extraction template. One author (U.S.) extracted
the relevant data from included studies, which was checked
by a second author (A.U.). There were no disagreements
between the 2 authors. The corresponding author of 1 study
included for ﬁnal analysis was contacted via e-mail for clar-
iﬁcation of information, but there was no response (4).
Data items. Information was extracted from each included
trial on the variables mentioned in the data eligibility
section.
Study quality and risk of bias in individual studies. To
assess the quality of the study, guidelines in Cochrane
Handbook for Systematic Reviews of Interventions were
followed (5). A scoring system to grade the study quality was
not used, as strongly discouraged by the Cochrane Collabo-
ration (5). To explore variability in study results (heteroge-
neity), we speciﬁed the following hypothesis before
conducting the analysis.We hypothesized that effect size may
differ according to the methodological quality of the studies;
hence, a random-effects model was to be primarily used.
Statistical analysis. Statistical analysis was performed by
1 author (U.S.) using Comprehensive Meta-analysis statis-
tical software (version 2.2.064) (Biostat Inc., Englewood,
New Jersey).
SUMMARY MEASURES. The primary outcome measure was
a reduction in risk of CI-AKI with ascorbic acid quanti-
ﬁed by computing the pooled risk ratio (RR) with 95%
conﬁdence interval (CI) using a random-effects model.
PLANNED METHOD OF ANALYSIS. In addition, inﬂuence of
using aﬁxed-effectsmodel onRRwas also assessed. The effect
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2169of removal of 1 study each time on RR was also assessed to
identify the impact of individual studies on pooled effect size.
Cumulative analysis was performed by organizing the studies
in chronological order to observe the trend in pooled RR over
time. Heterogeneity was quantiﬁed using I2 statistic (with
95%CI), which represents the percentage of the total variation
in estimated effects across studies that is due to heterogeneity
rather than to chance.Heterogeneity was graded afterHiggins
et al. (6): I2 values on the order of 25%, 50%, and 75%may be
considered as low, moderate, and high heterogeneity,
respectively.
RISK OF BIAS. The possibility of publication bias was assessed
by subjectively evaluating a funnel plot of the standard error of
a logarithm of RR for asymmetry. Because graphic represen-
tation is subjective, we also conducted Egger’s regression
asymmetry test as formal statistical test for publication bias (7).
To assess whether the entire effect was an artifact of bias,
Orwin’s fail-safe N formula was used (7). To assess howmuch
of an impact bias might have on effect size (RR), the Duval
and Tweedie trim and ﬁll method was used.We acknowledge
that other factors such a differences in trial quality or true study
heterogeneity could produce asymmetry in funnel plots.Figure 1 Flow Diagram of Study Selection
Flow of information through the different phases of systematic review from literature searc
controlled trial.Results
Study selection. The search of MEDLINE, Embase, and
Cochrane central database provided a total of 63 citations.
After adjusting for duplicates, 56 remained. Of these,
47 were discarded because, after reviewing the abstracts,
it appeared that these papers clearly did not meet the
eligibility criteria. One of these 47 articles was an RCT
reported as a conference abstract that, although ascorbic acid
was used in 1 treatment arm, but it did not report the
incidence of CI-AKI (percentage or number of cases) (8).
The authors were not able to be contacted; hence, the study
was excluded.
Nine RCTs were identiﬁed for inclusion in the review
and meta-analysis (4,9–16). Seven of these had full text
that was examined in more detail. Two were conference
abstracts that met the eligibility criteria and hence were
included in the analysis (13,16). No relevant RCTs were
identiﬁed from the hand search of relevant articles that
could be included. Similarly, no unpublished studies were
identiﬁed. There was no disagreement among the authors
regarding study selection. A ﬂow diagram of study selection
is presented in Figure 1.h to ﬁnal analysis. CI-AKI ¼ contrast-induced acute kidney injury; RCT ¼ randomized,
Table 1 Baseline Study Characteristics
First Author (Ref. #)
No. of
Patients
Recruited
Baseline Renal
Function Deﬁnition of CI-AKI Dose of Ascorbic Acid
Route of
Ascorbic Acid
Administration Control Arm
Spargias et al. (9) 238 SCr 1.2 mg/dl 0.5 mg/dl absolute or
25% relative SCr increase
2–5 days after procedure
3 g at least 2 h before procedure, 2 g night before
and morning after procedure. Hydration with NS
50–125 ml/h IV from time of randomization to
at least 6 h after procedure
Oral Placebo with IV hydration as in
ascorbic acid arm
Boscheri et al. (10) 143 SCr >120 mmol/l
(1.4 mg/dl)
25% increase in SCr from
baseline at 48 h
1 g ascorbic acid 20 min before exposure to CM;
500 ml NS 2 h before and 500 ml during
angiography and subsequent 6 h
Oral Placebo with IV hydration as in
ascorbic acid arm
Jo et al. (11) 212 SCr 1.1 mg/dl
and/or CrCl
clearance 60 ml/min
0.5 mg/dl absolute or
25% relative SCr increase
within 48 h of CM exposure
3 g (night before) and 2 g morning of procedure;
2 g night before and morning after procedure
(all doses 12 h apart)
Oral 1,200 mg N-acetylcysteine orally
bid day before and on day of
procedure
Zhou and Chen (12) 174 SCr 1.1 mg/dl and/or
eGFR <60 ml/min/1.73 m2
0.5 mg/dl absolute or
25% relative SCr increase
within 48 h of CM exposure
IV 3 g morning of procedure, oral 0.5 g on the night
of procedure and next morning (all doses
12 h apart). IV NS hydration 1 mg/kg/h for 4 h
before and at least 12 h after angiography
IV and oral IV NS hydration 1 mg/kg/h for
4 h before and at least 12 h
after angiography
Komiyama et al. (13) 70 Baseline renal
insufﬁciency
(threshold not
mentioned)
0.5 mg/dl absolute or
25% relative SCr
3 g before procedure, 2 g night and morning after
procedure (12 h apart). NS hydration 1.5–2.5 l
IV IV NS hydration 1.5–2.5 l
Brueck et al. (14) 520 CrCl 60 ml/min SCr >0.5 mg/dl (44 mmol/l)
within 72 h of CM exposure
500 mg in 250 ml NS infusion (over 30 min)
at 24 h and 1 h before exposure to CM.
NS (1 mg/kg/h) for 12 h before to 12 h after
CM exposure
IV Placebo (per ascorbic acid dose)
and IV NS (1 mg/kg/h) for
12 h before to 12 h after
CM exposure
Li and Chen (15) 149 Baseline renal
insufﬁciency
(threshold not
mentioned)
0.5 mg/dl absolute or
25% relative SCr
IV 3 g 2–4 h before procedure and oral 1.0 g on
days 1 and 2 after procedure. IV NS hydration
IV and oral IV NS hydration
Albabtain et al. (4) 243 SCr 1.3 mg/dl 0.5 mg/dl absolute increase in SCr
and/or 25% relative decrease
of CrCl, 4–5 days after procedure
3 g 2 h before procedure, 2 g after angiogram
and 2 g 24 h after angiogram. IV NS 50–125 ml/h
from randomization until at least 6 h after procedure
Oral IV NS hydration
Hamdi et al. (16) 202 Not declared,
baseline SCr:
98.6  29 mmol/l
25% increase in SCr 48–72 h
after angiogram
3 g 2 h before procedure, 2 g day after and next day Not reported IV NS hydration
Shown are the total number of recruited patients in each trial, deﬁnition of CI-AKI as used by included trial, dose of ascorbic acid used, and the treatment given to patients in control arm.
CI-AKI ¼ contrast-induced acute kidney injury; CM ¼ contrast media; CrCl ¼ creatinine clearance; eGFR ¼ estimated glomerular ﬁltration rate; IV ¼ intravenous; NS ¼ normal saline solution; SCr ¼ serum creatinine.
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2171Study characteristics. These are presented in Table 1.
METHODS. All 9 studies ﬁnally selected for the review and
meta-analysis were RCTs and all published in the English
language. All included studies had reported the incidence of
CI-AKI and had serum creatinine levels checked between 24 h
to 5 days.
PARTICIPANTS. All studies reported an adult population
undergoing coronary angiography. All studies had patients
with baseline renal impairment.
INTERVENTION AND OUTCOMES. The interventions and
outcomes are presented in Table 1.
Risks of bias within studies. All included trials were
randomized, thus minimizing the chance of bias within
studies compared with observational studies. The quality
of studies may be assessed from Table 2, which presents
the relevant study characteristics according to Cochrane
Handbook for Systematic Reviews of Interventions.
Results of individual studies. All studies reported the
incidence of CI-AKI as the number of cases, except 1
study by Hamdi et al. (16), for which event rate was
imputed. The event rate of the included studies is presented
in Figure 2.
Synthesis of results. Nine RCTs reported data on the
incidence of CI-AKI in 1,536 patients who had completed
the trial and were included in the ﬁnal analysis. Ascorbic
acid was given to 740 patients, whereas 796 patients were
in control group and received alternate treatment. The
overall incidence of CI-AKI in patients receiving ascorbic
acid was 9.59% compared with 16.83% in the control arm.
In the pooled analysis using a random-effects model,
patients receiving ascorbic acid had 33% less risk of CI-
AKI compared with the control group (RR: 0.672 [95%
CI: 0.466 to 0.969], p ¼ 0.034) (Fig. 2). Evaluation of the
95% CI shows that the range of risk lowering varied
from 54% to 4% with ascorbic acid. A low degree of
nonsigniﬁcant heterogeneity was present (I2 ¼ 27.49%,
chi-square ¼ 11.03, df ¼ 8, p ¼ 0.200).
Risk of bias across studies. Due to evidence of low
heterogeneity, a funnel plot was created to explore it and
assess any bias (Fig. 3). The funnel plot showed evidence
of minimal asymmetry that was quantiﬁed to be statisti-
cally nonsigniﬁcant by Egger’s regression intercept (in-
tercept ¼ 0.552 [95% CI: 1.428 to 2.533], df ¼ 7, p ¼
0.530). Orwin’s fail-safe N is 170, suggesting that there
would need to be >150 studies with a mean RR of 1.0
added to the analysis before the cumulative effect would
become trivial (deﬁned as an RR of 0.98). Given that we
were able to identify only 9 studies for the ﬁnal analysis, it
is quite unlikely that >150 studies were missed. Although
there is a possibility that a reduction in the risk of CI-AKI
with ascorbic acid is overstated, it is unlikely that the actual
risk is zero. Using a random-effects model, trim and ﬁll
method suggested no asymmetry on the right of the mean
and 1 study on the left of the mean, which if trimmed, the
Figure 2 Forest Plot of Included Studies
The event rate in different study arms is presented alongside the computed risk ratio (95% conﬁdence interval [CI] (lower and upper limit) with p value. Forest plot shows effect
size (solid squares) with 95% CI (black line through the solid squares), in terms of risk ratio for individual studies and pooled risk ratio (open diamonds) for ﬁxed- and random-
effects model at the bottom. Studies favoring reduction of risk with ascorbic acid are on the left of the center line, and studies favoring other treatment options are on right of
the center line. CI-AKI ¼ contrast-induced acute kidney injury.
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2172imputed RR would be 35% (instead of 33%). These
analyses reveal that the impact of bias was most likely
trivial.
Additional analyses. Use of a ﬁxed-effects model showed
a 33% (95% CI: 13% to 49%) lower risk with ascorbic acid
(RR: 0.670 [95% CI: 0.511 to 0.878], p ¼ 0.004) (Fig. 2).
Although the degree of signiﬁcance was higher compared
with a random-effects model, the pooled effect size was
similar, with minor variation in the 95% CI.
The effect of removal of individual studies on the pooled
RR using a random-effects model was assessed using a forestFigure 3
Funnel Plot for Subjective Assessment of
Bias Among the Included Studies
Studies with larger sample size tend to accumulate at the top of the funnel and
close to the center line, with small studies toward the base. Funnel plot appears
to have minimal asymmetry.plot, showing that it favored ascorbic acid use to protect
against CI-AKI at each step (Fig. 4).
To assess how the trend in RR had changed from the
earliest to latest studies, a cumulative analysis was performed
with studies arranged in chronological order (Fig. 5). The
second row in Figure 5 represents a summary analysis
comprising the ﬁrst 2 studies, the third row represents
a summary analysis comprising the ﬁrst 3 studies, and so on.
There was a small but consistent cumulative trend toward
a beneﬁt with ascorbic acid. As none of the studies had ex-
cessively large sample size, we did not perform a cumulative
analysis to try to assess its impact on effect size.
Three studies had a sizable proportion of patients lost to
follow up after randomization (12,14,17). After excluding
these 3 studies from the analysis, it was observed that the
beneﬁt of ascorbic acid for nephroprotection increases,
with a further reduction in nonsigniﬁcant minimal het-
erogeneity and no evidence of publication bias (RR:
0.530 [95% CI: 0.349 to 0.860], p ¼ 0.003; I2 ¼ 9.120, chi-
square ¼ 5.502, df ¼ 5, p ¼ 0.358; Egger’s regression
intercept ¼ 1.086 [95% CI: 2.570 to 4.743], df ¼ 4,
p ¼ 0.455).Discussion
This pooled statistical analysis of systematically selected
RCTs provides robust evidence that ascorbic acid reduces
the risk of CI-AKI, albeit by somewhat small magnitude,
in patients undergoing coronary angiography compared
with alternate treatment strategies. Because participants
of these studies had documented pre-existing renal
Figure 4 Forest Plot Using a Random-Effects Model Demonstrating the Effect of Removal of Individual Studies on Pooled Effect Size
A consistent trend in favor of ascorbic acid as a nephroprotective agent was observed at each step. Small solid squares indicate effect sizes following removal of individual
studies. Open diamonds indicates pooled effect size. CI ¼ conﬁdence interval.
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2173insufﬁciency, this indicates that ascorbic acid is effective
in offering nephroprotection in this patient group. The
GRADE (Grading of Recommendations Assessment,
Development, and Evaluation) system for grading evidence
can be used to assess various factors that may decrease the
quality of this evidence (18).
Study limitations. The trials included for meta-analysis
did not consistently report optimal randomization conceal-
ment (Table 2) and had a variable lack of blinding and the
outcome measures were not subjective; hence, these may not
be considered serious limitations. None of the trials wasFigure 5 Cumulative Analysis of Included Studies in Chronological O
The second bar with a black-ﬁlled box in the cumulative risk ratio forest plot indicates cum
plot indicates the cumulative analysis of ﬁrst 3 studies and so on. A somewhat consisteterminated prematurely, and there was no evidence of
selective reporting.
INCONSISTENT RESULTS. Heterogeneity among the trials was
minimal. This may be due to true heterogeneity of the study
populations. Also important to note is that there was vari-
ability among studies about the route in which ascorbic acid
was administered. The bioavailability of oral and intravenous
administration of ascorbic acid differ (19), and this can affect
the drug efﬁcacy and hence variation of effect sizes between
studies.rder
ulative analysis of the ﬁrst 2 studies. The third bar with a black-ﬁlled box in the forest
nt trend toward beneﬁt with ascorbic acid is evident. CI ¼ conﬁdence interval.
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2174INDIRECTNESS OF EVIDENCE. All included trials reported
head-to-head comparison of ascorbic acid and alternate
treatment; hence, there was no evidence of indirectness.
IMPRECISION. None of the trials had very small sample size
compared with others, and event rate was not negligible in
studies.
PUBLICATION BIAS. Publication bias was nonsigniﬁcant and
was found not to affect the pooled effect size of our
meta-analysis.
Thus, it can be cautiously said that results of this
systematic review with meta-analysis are reliable. Would it
be possible to overturn the results of this meta-analysis by
conducting another clinical trial? It is difﬁcult to answer the
question of what would the sample size be for the future trial
because there are so many unknowns (e.g., sample size,
effect size, risk in each group). But assuming that the true
effect size (odds ratio) in the population is 1, indicating
no difference between groups, and assuming a risk of 15% in
each group (based on the available study data), then a total
sample size of 250 (125 patients in each group) will change
the conclusions of the meta-analysis provided that the
observed effect size is at least as large as the true effect
size of 1.
It is to be noted that no trial can be conducted that is
guaranteed to change the conclusions of the meta-analysis.
Also, it is easier to conclude a signiﬁcant difference rather
than a nonsigniﬁcant difference. If the meta-analysis result is
changed to nonsigniﬁcant, then the best that we can say is
that there is insufﬁcient evidence of a beneﬁcial effect of
ascorbic acid. The additional analyses performed in this
meta-analysis, such as the effect of removal of 1 study at
a time (Fig. 4) and cumulative analysis (Fig. 5), also show
a persistent beneﬁt of ascorbic acid against CI-AKI. Because
of these reasons, it would therefore not be advisable to
conduct such a trial.
How ascorbic acid may offer nephroprotection. The
exact mechanism by ascorbic acid may offer neph-
roprotection is unclear, but it has been widely used due to
its antioxidant property. ROS-induced oxidative stress and
renal vasoconstriction have been implicated in the etiology
of CI-AKI. Hydroxyl radical (OH$) is one of many free
radicals that can cause oxidative stress. The Haber Weiss/
Fenton reaction cycle governs the generation of OH$ from
hydrogen peroxide (H2O2) and superoxide radical (O2$
),
with reduction of ferric to ferrous by O2$
, ferrous acting
as a catalyst for this cycle. Ascorbate is an efﬁcient scav-
enger of ROS such as O2$
, H2O2, and OH$ can there-
fore reduce the oxidative stress (1). Being a reducing agent,
ascorbic acid has the ability to reduce ferric to ferrous, thus
potentially promoting the generation of ROS and acting as
a pro-oxidant. However, this pro-oxidant effect has been
demonstrated mainly in vitro; corresponding in vivo data
has been inconsistent (2,20,21). Radox-active free iron
is required for the Haber Weiss/Fenton reaction, but
physiologically this labile iron pool is kept at the lowestsufﬁcient level by keeping iron in bound form, the excep-
tion being patients with iron overload conditions such as
hemochromatosis (22). Under physiological conditions
in vivo, ascorbate seems to predominantly maintain its
antioxidant effect (2,20,21,23). Ascorbic acid acts as
an antioxidant by donating an electron to potentially
damaging oxidizing radicals; this 1-electron oxidation of
AH (reduced circulating form of ascorbic acid) results in
the production of the ascorbyl radical (A$), also called
semidehydroascorbic acid. As a result, the reactive free
radical is reduced (24). Further donation of an electron
(double oxidation) results in generation of stable dehy-
droascorbic acid. Among the trials included in this
systematic review, the antioxidant effect of ascorbic acid
was demonstrated by Spargias et al. (9). Ascorbic acid has
also been reported to cause vasodilation (25,26). This effect
may be independent of its effect to ameliorate ROS-
induced endothelial dysfunction (27). These ﬁndings are,
however not consistent (28).
In contrast to one’s expectation that ascorbic acid can
cause acidiﬁcation of urine, there is consistent evidence
that ascorbic acid in a daily dose range of 2 to 6 g/day
in divided doses (29–31) (which is equivalent to the
maximum daily dose used in the RCTs included in the
meta-analysis) does not acidify the urine. Surprisingly, it can
increase the urine pH (30). Because an acidic environment,
which is typical of tubular urine, promotes free-radical
production (32) and high pH of normal extracellular ﬂuid
inhibits it (33,34), alkalinizing renal tubular ﬂuid with phar-
macological agents is a logical strategy to reduce renal injury.
Effect of route of administration on the efﬁcacy of
ascorbic acid. After oral intake, ascorbic acid is absorbed by
active transport in the intestine (35). Most of it (80% to
90%) is absorbed when the intake is up to 100 mg/day. With
an increase in ascorbic acid intake, the corresponding plasma
concentration increases, reaching a plateau at a dose of 90 to
150 mg/day (36). It is freely transported into cells, including
leukocytes and red blood cells, becoming saturated with
ascorbic acid at doses between 100 and 200 mg/day (19). In
contrast to this, intravenous route tends to achieve higher
peak plasma concentration (e.g., 3 g of intravenous ascorbic
acid produces a peak plasma concentration of 1,760 mmol/l
vs. 206 mmol/l for oral route at same dose) (19). After
intravenous administration, predicted peak urine concen-
trations of ascorbic acid can be as much as 140-fold higher
compared with oral administration (19). Similar to the high
requirement of ascorbic acid in individuals with higher
oxidative stress such as in smokers (37), it is possible that
a higher plasma concentration of ascorbic acid, which is
achievable with higher intravenous doses, may be more
beneﬁcial in individuals with pre-existing renal insufﬁciency.
This meta-analysis did not compare the pooled treatment
effect of RCTs using exclusive peroral and intravenous
ascorbic acid administration because only 2 RCTs used the
intravenous route exclusively, and their pooled analysis
would not have been meaningful.
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Ascorbic acid has the potential to protect against CI-AKI in
patients with pre-existing renal impairment and can form
part of effective prophylactic pharmacological regimens. The
precise mechanism by which it may do so is as unclear, as is
the etiology of CI-AKI. To assess its full potential as
a nephroprotective agent, further investigation is warranted
regarding its optimal dose and route of administration,
which affect its bioavailability.
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